EG24226A - Formulation - Google Patents

Formulation

Info

Publication number
EG24226A
EG24226A EG20001205A EG20001205A EG24226A EG 24226 A EG24226 A EG 24226A EG 20001205 A EG20001205 A EG 20001205A EG 20001205 A EG20001205 A EG 20001205A EG 24226 A EG24226 A EG 24226A
Authority
EG
Egypt
Prior art keywords
formulation
Prior art date
Application number
EG20001205A
Other languages
English (en)
Inventor
Brown B Daniel
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10861288&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EG24226(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of EG24226A publication Critical patent/EG24226A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
EG20001205A 1999-09-21 2000-09-20 Formulation EG24226A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9922271.3A GB9922271D0 (en) 1999-09-21 1999-09-21 Formulation

Publications (1)

Publication Number Publication Date
EG24226A true EG24226A (en) 2008-11-10

Family

ID=10861288

Family Applications (1)

Application Number Title Priority Date Filing Date
EG20001205A EG24226A (en) 1999-09-21 2000-09-20 Formulation

Country Status (37)

Country Link
US (3) US6599897B1 (de)
EP (1) EP1218009B1 (de)
JP (1) JP2003509461A (de)
KR (1) KR100748823B1 (de)
CN (3) CN1899288A (de)
AR (1) AR032596A1 (de)
AT (1) ATE288272T1 (de)
AU (1) AU776292B2 (de)
BG (1) BG65469B1 (de)
BR (1) BR0014107A (de)
CA (1) CA2383131A1 (de)
CO (1) CO5180585A1 (de)
CZ (1) CZ301585B6 (de)
DE (1) DE60017923T2 (de)
DK (1) DK1218009T3 (de)
EE (1) EE200200150A (de)
EG (1) EG24226A (de)
ES (1) ES2235941T3 (de)
GB (2) GB9922271D0 (de)
HK (1) HK1047706B (de)
HU (1) HUP0203531A3 (de)
IL (2) IL148440A0 (de)
IS (1) IS2139B (de)
MX (1) MXPA02002627A (de)
MY (1) MY130208A (de)
NO (1) NO320908B1 (de)
NZ (1) NZ517549A (de)
PL (1) PL198824B1 (de)
PT (1) PT1218009E (de)
RU (1) RU2256453C2 (de)
SI (1) SI1218009T1 (de)
SK (1) SK286884B6 (de)
TR (1) TR200200716T2 (de)
TW (1) TWI226832B (de)
UA (1) UA73529C2 (de)
WO (1) WO2001021179A1 (de)
ZA (1) ZA200201709B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9922271D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Formulation
SE0102855D0 (sv) * 2001-08-27 2001-08-27 Astrazeneca Ab Method of treatment
EP1448169A1 (de) * 2001-11-07 2004-08-25 Fujisawa Pharmaceutical Co., Ltd. Methode zur verbesserung der löslichkeit von schwer-dispergierbaren medikamenten
JP4514473B2 (ja) * 2004-02-23 2010-07-28 富士通株式会社 コンピュータシステム、中央装置及びプログラム実行方法
UA88792C2 (ru) * 2004-11-10 2009-11-25 Таргасепт, Інк. Гидроксибензоатные соли метаникотиновых соединений
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
WO2006117700A2 (en) * 2005-04-21 2006-11-09 Medichem, S.A. Process for preparing quetiapine and quetiapine fumarate
EP1976487A2 (de) 2006-01-25 2008-10-08 Astron Research Limited Dosierung mit verzögerter freigabe von phenothiazin-derivaten mit kanalisierern
EP2357174A1 (de) * 2006-05-09 2011-08-17 AstraZeneca AB Salzformen von (2S)-(4E)-N-Methyl-5-[(5-Isopropoxy)pyridin-3-yl]-4-Penten-2-Amin
TWI389889B (zh) * 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
CA2657202A1 (en) * 2006-07-28 2008-01-31 Farmaprojects, S.A. Extended release pharmaceutical formulation of metoprolol and process for its preparation
CL2007002684A1 (es) * 2006-09-15 2008-06-27 Astrazeneca Ab Targacept Inc Combinacion que comprende un antipsicotico y (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina; composicion farmaceutica que la comprende; kit farmaceutico; y uso para tratar perjuicio cognitivo y/o trastorno psicoticos.
US8623861B2 (en) * 2006-11-03 2014-01-07 Xin-Min Li Method of treating demyelination diseases
EP2112923A1 (de) * 2007-01-22 2009-11-04 Targacept Inc. Intranasale, orale und sublinguale verabreichung von metanikotin-analogen
ES2352299T3 (es) * 2007-02-14 2011-02-17 Laboratorios Lesvi, S.L. Composiciones farmacéuticas que contienen fumarato de quetiapina.
RU2492695C2 (ru) * 2008-02-27 2013-09-20 КРАФТ ФУДЗ ГЛОБАЛ БРЭНДЗ ЭлЭлСи Многозональное кондитерское изделие
DK2262486T3 (da) 2008-08-01 2013-03-25 Krka Tovarna Zdravil D D Novo Mesto Quetiapin sammensætning
DE102008046650A1 (de) 2008-09-10 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Quetiapin enthaltende Retardtablette
US8715699B2 (en) 2009-12-31 2014-05-06 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same
US20110223207A1 (en) 2010-03-11 2011-09-15 Travis Mickle Fatty Acid Conjugates of Quetiapine, Process for Making and Using the Same
KR20130081221A (ko) 2010-05-20 2013-07-16 아스트라제네카 아베 아릴 치환된 올레핀계 아민의 신규 제조 방법
DE102010033527A1 (de) 2010-08-05 2012-02-09 Acino Pharma Ag Quetiapin-Tabletten
DE102011115690A1 (de) 2011-10-11 2013-04-11 Acino Pharma Ag Quetiapin enthaltende Formulierungen
US9993486B1 (en) 2017-06-19 2018-06-12 Tlc Therapeutics, Llc Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability
AU2021263558B2 (en) * 2020-04-29 2026-02-26 Stepan Company Solid compositions containing amine, protonated amine or quaternary ammonium compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
GB8705574D0 (en) * 1987-03-10 1987-04-15 Ici Plc Preparation of thiazepine compound
DK0416773T3 (da) * 1989-08-31 1993-03-29 Takeda Chemical Industries Ltd Vitamin B12 præparat
IT1250701B (it) * 1991-07-24 1995-04-21 Angelini Francesco Ist Ricerca Composizione farmaceutica solida per uso orale a base di dapiprazolo
JPH06100602A (ja) * 1992-09-18 1994-04-12 Asahi Chem Ind Co Ltd 経口固形製剤およびその製造方法
US5397576A (en) * 1992-09-23 1995-03-14 Hoffmann-La Roche Inc. Spray triturated micronutrient compositions
RU2115650C1 (ru) * 1992-11-09 1998-07-20 Дзе Бутс Компани ПЛС 2,3,4,5-тетрагидро-1,4-бензотиазепины, их стереоизомеры или их фармацевтически приемлемые соли, способ их получения, фармацевтическая композиция, обладающая противосудорожным действием
ZA973433B (en) * 1996-04-24 1997-12-10 Shionogi & Co A sertindole-containing preparation and a method for producing the same.
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
GB9611328D0 (en) * 1996-05-31 1996-08-07 Zeneca Ltd Pharmaceutical compositions
CA2266448A1 (en) * 1996-09-24 1998-04-02 Eli Lilly And Company Coated particle formulation
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
GB9922271D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Formulation

Also Published As

Publication number Publication date
MXPA02002627A (es) 2002-07-30
EP1218009B1 (de) 2005-02-02
HUP0203531A3 (en) 2004-12-28
IS6308A (is) 2002-03-19
BG65469B1 (bg) 2008-09-30
WO2001021179A1 (en) 2001-03-29
SI1218009T1 (en) 2005-06-30
NO320908B1 (no) 2006-02-13
US20040228914A1 (en) 2004-11-18
AR032596A1 (es) 2003-11-19
IS2139B (is) 2006-08-15
ATE288272T1 (de) 2005-02-15
GB9922271D0 (en) 1999-11-17
CN1331472C (zh) 2007-08-15
CN1626094A (zh) 2005-06-15
NZ517549A (en) 2003-10-31
CN1188130C (zh) 2005-02-09
MY130208A (en) 2007-06-29
PL357369A1 (en) 2004-07-26
KR100748823B1 (ko) 2007-08-13
GB0021406D0 (en) 2000-10-18
NO20021394D0 (no) 2002-03-20
TR200200716T2 (tr) 2002-06-21
SK286884B6 (sk) 2009-07-06
EP1218009A1 (de) 2002-07-03
BR0014107A (pt) 2002-08-20
DE60017923D1 (de) 2005-03-10
SK3722002A3 (en) 2002-07-02
UA73529C2 (uk) 2005-08-15
HUP0203531A2 (hu) 2003-02-28
PL198824B1 (pl) 2008-07-31
IL148440A (en) 2007-07-04
DE60017923T2 (de) 2006-01-12
US7022692B2 (en) 2006-04-04
CN1899288A (zh) 2007-01-24
CA2383131A1 (en) 2001-03-29
CN1374867A (zh) 2002-10-16
AU7302300A (en) 2001-04-24
PT1218009E (pt) 2005-05-31
KR20020033186A (ko) 2002-05-04
IL148440A0 (en) 2002-09-12
BG106509A (en) 2002-12-29
ZA200201709B (en) 2003-05-28
TWI226832B (en) 2005-01-21
US6599897B1 (en) 2003-07-29
ES2235941T3 (es) 2005-07-16
EE200200150A (et) 2003-04-15
US20060159768A1 (en) 2006-07-20
CZ2002974A3 (cs) 2002-06-12
CZ301585B6 (cs) 2010-04-21
JP2003509461A (ja) 2003-03-11
DK1218009T3 (da) 2005-05-09
AU776292B2 (en) 2004-09-02
HK1047706A1 (en) 2003-03-07
RU2256453C2 (ru) 2005-07-20
CO5180585A1 (es) 2002-07-30
NO20021394L (no) 2002-03-20
HK1047706B (en) 2005-06-10

Similar Documents

Publication Publication Date Title
HUP0201489A3 (en) New formulation
GB2359254B (en) Formulation
EP1156812A4 (de) Multipartikuläre formulierung
EG24226A (en) Formulation
GB0000891D0 (en) Formulation
IL145995A0 (en) Use
GB9913536D0 (en) Use
GB9902304D0 (en) Formulation
GB9905898D0 (en) Controlled-dose formulation
AU140373S (en) Bumbag
AU141428S (en) Turnpiece
GB9927614D0 (en) Sterliant formulation
GB9914798D0 (en) Ensure
GB9919971D0 (en) Use
GB9902236D0 (en) Formulation
GB9915584D0 (en) Formulation
GB9902089D0 (en) Formulation
GB9917952D0 (en) Formulation
GB9908776D0 (en) Formulation
GB9923538D0 (en) Formulation
GB9919060D0 (en) Combination formulation
GB9910118D0 (en) Formulations
EG22401A (en) Set 3c1-strong
CA87158S (en) Pendulette
GB9921193D0 (en) Disinfectant formulation